SRRA Sierra Oncology Inc.

0.23
0  1%
Previous Close 0.23
Open 0.22
Price To Book 0.18
Market Cap 17,499,465
Shares 74,688,283
Volume 1,293,017
Short Ratio
Av. Daily Volume 575,220
Stock charts supplied by TradingView

NewsSee all news

  1. Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

    - MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients

  2. Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

    - "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug

  3. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra

  4. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /CNW/ - Sierra

  5. Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Discontinued following poor efficacy - June 2016
PNT2258
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - cancer
Development suspended - June 2016
PNT2258
Richter's Transformation
Phase 1/2 preliminary data ASCO June 1, 2019 noted stable disease rate of 32%.
SRA737
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Phase 1/2 preliminary data of ORR 30% at ASCO June 1, 2019. 8am.
SRA737 + Low-Dose Gemcitabine
Solid Tumors
Phase 3 trial initiation announced November 20, 2019 with top-line data due 4Q 2021.
Momelotinib - MOMENTUM
Myelofibrosis
Presentation at ASH December 7, 2019 at 5:30pm EST.
Momelotinib - (Simplify 1)
Myelofibrosis

Latest News

  1. Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

    - MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic patients

  2. Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

    - "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER, Nov. 14, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug

  3. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra

  4. Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

    - Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7, 2019 /CNW/ - Sierra

  5. Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  6. Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  7. Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

    VANCOUVER, Nov. 6, 2019 /CNW/ - Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a

  8. Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

    - New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients - VANCOUVER, Nov.

  9. Sierra Oncology Reports Third Quarter 2019 Results

    - MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER, Nov. 4, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing